Quantification of adaptive immune cell genomes in a complex mixture of cells

• US 9,279,159 B2
• Filed: 10/19/2012
• Issued: 03/08/2016
• Est. Priority Date: 10/21/2011
• Status: Active Grant

• Current Assignee: Adaptive Biotechnologies Corp., Fred Hutchinson Cancer Center
• Original Assignee: Adaptive Biotechnologies Corp., Fred Hutchinson Cancer Research Center (Fred Hutchinson Cancer Research Center|Argus Genetics|Mars)
• Inventors: Robins, Harlan S., Livingston, Robert J., Bielas, Jason H.
• Primary Examiner(s): Mummert, Stephanie K
• Assistant Examiner(s): PRIEST, AARON A
• Application Number:
  US13/656,265
• Publication Number:
  US 20130288237A1
• Time in Patent Office: 1,236 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 1/6888 for detection or identification of organisms
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.

Claims

1. A method for quantifying a relative representation of adaptive immune cells in a solid tumor sample that comprises a mixture of cells comprising adaptive immune cells and cells that are not adaptive immune cells, the method comprising:

(a) amplifying DNA molecules comprising rearranged CDR3 regions from said sample by performing a multiplex quantitative polymerase chain reaction (qPCR) using;

(1) a plurality of V-segment oligonucleotide primers comprising sequences selected from the group consisting of SEQ ID NOs;

1-52, 66-68, 221-238, 255-260, 262-267, 269, 272, 283, 286, 291, 292, 294-297, 301-326, 330, 338, 382, 405, 447-484, 644-695, 709-839, and 843-879 that are each capable of specifically hybridizing to at least one polynucleotide encoding a T cell receptor (TCR) V-region polypeptide or an immunoglobulin (Ig) V-region polypeptide, wherein the plurality of V-segment oligonucleotide primers specifically hybridize to at least 90% of-all functional TCR or Ig V-encoding gene segments that are present in the sample, and

(2) a plurality of J-segment oligonucleotide primers comprising sequences selected from the group consisting of SEQ ID NOs;

53-63, 65, 215-220, and 247 that are each capable of specifically hybridizing to at least one polynucleotide encoding a T cell receptor (TCR) J-region polypeptide or an immunoglobulin (Ig) J-region polypeptide, wherein the plurality of J-segment oligonucleotide primers specifically hybridize to at least 90% of all functional TCR or Ig J-encoding gene segments that are present in the sample, to produce a multiplicity of amplified rearranged TCR or Ig CDR3 DNA molecules from the adaptive immune cells in the sample;

(b) measuring a plurality of first signal levels at a plurality of time points detected from said amplified rearranged TCR or Ig CDR3 DNA molecules;

(c) comparing the plurality of first signal levels with a plurality of second signal levels detected from amplification of rearranged TCR or Ig CDR3 DNA molecules of known concentrations, thereby quantifying a relative amount of adaptive immune cell DNA; and

(d) determining, from the relative amount of adaptive immune cell DNA quantified in (c), the relative representation of adaptive immune cells in the solid tumor sample.

2. The method of claim 1, wherein each amplified rearranged TCR or Ig CDR3 DNA molecule is less than 600 nucleotides in length.

3. The method of claim 1, wherein each functional TCR or Ig V-encoding gene segment comprises a V gene recombination signal sequence (RSS) and each functional TCR or Ig J-encoding gene segment comprises a J gene RSS, and wherein each amplified rearranged DNA molecule comprises (i) at least 10, 20, 30 or 40 contiguous nucleotides of a sense strand of the TCR or Ig V-encoding gene segment, said at least 10, 20, 30 or 40 contiguous nucleotides being situated 5′

to the V gene RSS and (ii) at least 10, 20 or 30 contiguous nucleotides of a sense strand of the TCR or Ig J-encoding gene segment, said at least 10, 20 or 30 contiguous nucleotides being situated 3′

to the J gene RSS.

4. The method of claim 1, further comprising detecting a presence of at least ten adaptive immune cells per 10,000 cells in the mixture of cells.

5. The method of claim 1, wherein the adaptive immune cells are T cells.

6. The method of claim 1, wherein the adaptive immune cells are B cells.

7. The method of claim 1, wherein the sample is fresh tissue, frozen tissue, or fixed tissue.

8. The method of claim 1, wherein the rearranged TCR or Ig CDR3-encoding regions are selected from rearranged TCRα

CDR3-encoding regions, TCRβ

CDR3-encoding regions, TCRγ

CDR3-encoding regions, TCRδ

CDR3-encoding regions, IgH CDR3-encoding regions, Igκ

CDR3-encoding regions, and Igλ

CDR3-encoding regions.

9. The method of claim 1, wherein the sample comprises human cells, mouse cells, or rat cells.

10. The method of claim 1, wherein the sample comprises somatic tissue.

11. The method of claim 10, wherein the somatic tissue is from a subject having an autoimmune disease and the tissue is targeted by an autoimmune reaction.

12. The method of claim 11, wherein the autoimmune disease is selected from type 1 diabetes, rheumatoid arthritis, multiple sclerosis, Crohn'"'"'s disease, Graves'"'"' disease, Addison'"'"'s disease, celiac disease, Sjö

gren'"'"'s, psoriasis, Guillian-Barre syndrome, and myasthenia gravis.

13. The method of claim 10, wherein the somatic tissue comprises neoplastic tissue.

14. The method of claim 13, wherein the neoplastic tissue is obtained or derived from a solid tumor.

15. The method of claim 10, wherein the somatic tissue is from a transplanted organ.

16. The method of claim 15, wherein the transplanted organ is selected from liver, lung, kidney, heart, spleen, pancreas, skin, intestine, and thymus.

17. The method of claim 1, wherein the plurality of V-segment oligonucleotide primers and the plurality of J-segment oligonucleotide primers are RN2 modified.

25. The method of claim 1 or 18, wherein the first DNA signal level is measured by detecting fluorescence of a labeled probe or of multiple labeled probes that specifically hybridize to the multiplicity of amplified rearranged DNA molecules and the second DNA signal level is measured by detecting fluorescence of a labeled probe or of multiple labeled probes that specifically hybridize to the amplification products of the control adaptive immune cell template DNA.

26. The method of claim 25, wherein the labeled probe or one or more of the multiple labeled probes that specifically hybridizes to the multiplicity of amplified rearranged DNA molecules comprises a sequence selected from SEQ ID NOS:

66 and 709-839.

27. The method of claim 1, wherein said plurality of amplified rearranged TCR or Ig CDR3 DNA molecules comprises at least 10, 10², 10³, 10⁴, 10⁵, or 10⁶ DNA molecules.

28. The method of claim 1, wherein each V-segment oligonucleotide primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional TCR or Ig V encoding gene segment.

29. The method of claim 1, wherein each J-segment oligonucleotide primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional TCR or Ig J encoding gene segment.

32. The method of claim 1, wherein determining, from the relative amount of adaptive immune cell DNA quantified in (c), the relative representation of adaptive immune cells in the solid tumor sample comprises comparing the relative amount of adaptive immune cell DNA with a total concentration of DNA in the sample.

33. The method of claim 32, further comprising determining a total concentration of DNA in the sample by determining a level of control genes amplified in a PCR reaction using primers capable of amplifying said control genes.

34. The method of claim 32, further comprising determining a total concentration of DNA by dividing the amount of total DNA extracted from the sample by the average weight of a single genome.

18. A method for assessing an effect of a therapeutic treatment on at least one tissue of a subject, the method comprising:

(I) obtaining one or a plurality of samples from a first tissue of the subject at one or a plurality of time points prior to administering the therapeutic treatment, wherein the sample contains DNA from a mixture of cells, the mixture comprising adaptive immune cells and cells that are not adaptive immune cells;

(II) obtaining one or a plurality of samples from a second tissue of the subject at one or a plurality of time points after administering the therapeutic treatment, wherein the sample contains DNA from a mixture of cells, the mixture comprising adaptive immune cells and cells that are not adaptive immune cells;

(III) for each of said samples from (I) and (II);

(a) amplifying nucleic acid molecules from said sample by performing a quantitative multiplex polymerase chain reaction (qPCR) using

(i) a plurality of V-segment oligonucleotide primers comprising sequences selected from the group consisting of SEQ ID NOs;

1-52, 66-68, 221-238, 255-260, 262-267, 269, 272, 283, 286, 291, 292, 294-297, 301-326, 330, 338, 382, 405, 447-484, 644-695, 709-839, and 843-879 that are each capable of specifically hybridizing to at least one polynucleotide encoding a T cell receptor (TCR) V-region polypeptide or an immunoglobulin (Ig) V-region polypeptide, wherein the plurality of V-segment oligonucleotide primers specifically hybridize to at least 90% of all functional TCR or Ig V-encoding gene segments that are present in the sample, and

(ii) a plurality of J-segment oligonucleotide primers comprising sequences selected from the group consisting of SEQ ID NOs;

53-63, 65, 215-220, and 247 that are each capable of specifically hybridizing to at least one polynucleotide encoding a T cell receptor (TCR) J-region polypeptide or an immunoglobulin (Ig) J-region polypeptide, wherein the plurality of J-segment oligonucleotide primers specifically hybridize to at least 90% of all functional TCR or Ig J-encoding gene segments that are present in the sample, to produce a multiplicity of amplified rearranged TCR or Ig CDR3 DNA molecules from the adaptive immune cells in the sample;

(b) measuring first DNA signal levels at a plurality of time points that are detectable in said multiplicity of amplified rearranged TCR or Ig DNA molecules of (a) to generate a qPCR signal profile;

(c) comparing the qPCR signal profile in (b) to a standard signal profile detected from amplification of rearranged TCR or Ig CDR3 DNA molecules of known DNA concentrations, and therefrom quantifying a relative amount of adaptive immune cell DNA in the sample; and

(d) determining, from the relative amount of adaptive immune cell DNA quantified in (c), the relative representation of adaptive immune cell DNA in the sample; and

(IV) comparing the relative representation of adaptive immune cells in at least one sample obtained at a time point prior to administering the therapeutic treatment to the relative representation of adaptive immune cells in at least one sample obtained at a time point after administering the therapeutic treatment, and thereby assessing an effect of the therapeutic treatment on relative representation of adaptive immune cells in at least one tissue of a subject.

19. The method of claim 18, wherein the first and second tissues are the same tissue.

20. The method of claim 18, wherein the first and second tissues are different tissues.

21. The method of claim 18, further comprising determining a dose-related effect of the therapeutic treatment by analyzing a plurality of samples from the second tissue of the subject obtained at a plurality of time points after administering the therapeutic treatment a plurality of different dosages.

22. The method of claim 18, further comprising determining a prognosis for the subject receiving the therapeutic treatment by determining an altered relative representation of adaptive immune cells in at least one sample obtained at a time point after administering the therapeutic treatment, compared to the relative representation of adaptive immune cells in at least one sample obtained at a time point prior to administering the therapeutic treatment, which indicates an effect of the therapeutic treatment on relative representation of adaptive immune cells in at least one tissue of a subject.

23. The method of claim 22, wherein

(i) the subject has cancer and an increased relative representation of adaptive immune cells in at least one sample obtained at a time point after administering the therapeutic treatment compared to the relative representation of adaptive immune cells in at least one sample obtained at a time point prior to administering the therapeutic treatment, indicates a beneficial effect of the therapeutic treatment;

or

(ii) the subject has an autoimmune disease and a decreased relative representation of adaptive immune cells in at least one sample obtained at a time point after administering the therapeutic treatment compared to the relative representation of adaptive immune cells in at least one sample obtained at a time point prior to administering the therapeutic treatment, indicates a beneficial effect of the therapeutic treatment;

or

(iii) the subject has a transplanted organ and a decreased relative representation of adaptive immune cells in at least one sample from the transplanted organ obtained at a time point after administering the therapeutic treatment compared to the relative representation of adaptive immune cells in at least one sample from the transplanted organ obtained at a time point prior to administering the therapeutic treatment, indicates a beneficial effect of the therapeutic treatment.

24. The method of claim 18, further comprising determining a polynucleotide sequence for each amplified rearranged DNA molecule from the population of adaptive immune cells in the sample.

30. The method of claim 18, wherein each V-segment oligonucleotide comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional TCR or Ig V encoding gene segment.

31. The method of claim 19, wherein each J-segment oligonucleotide primer comprises a nucleotide sequence of at least 15 contiguous nucleotides that is complementary to at least one functional TCR or Ig J encoding gene segment.

35. A method for quantifying the relative representation of adaptive immune cells in a sample that comprises a mixture of cells, the mixture comprising adaptive immune cells and cells that are not adaptive immune cells, the method comprising:

(a) distributing template DNA extracted from the sample to form a set of assay samples,

(b) amplifying said template DNA in the set of assay samples in a multiplex digital polymerase chain reaction (dPCR) that comprises;

(1) (i) a plurality of V-segment oligonucleotide primers comprising sequences selected from the group consisting of SEQ ID NOs;

1-52, 66-68, 221-238, 255-260, 262-267, 269, 272, 283, 286, 291, 292, 294-297, 301-326, 330, 338, 382, 405, 447-484, 644-695, 709-839, and 843-879 that are each independently capable of specifically hybridizing to at least one polynucleotide encoding a T cell receptor (TCR) V-region polypeptide or an immunoglobulin (Ig) V-region polypeptide, and

(ii) a plurality of J-segment oligonucleotide primers comprising sequences selected from the group consisting of SEQ ID NOs;

53-63, 65, 215-220, and 247 that are each independently capable of specifically hybridizing to at least one polynucleotide encoding a T cell receptor (TCR) J-region polypeptide or an immunoglobulin (Ig) J-region polypeptide,

wherein the V-segment and J-segment primers are capable of amplifying in said multiplex dPCR at least 90% of all rearranged TCR or Ig CDR3-encoding regions in the sample to produce a multiplicity of amplified rearranged DNA molecules from the adaptive immune cells in the test sample; and

(2) a set of control primers to produce an internal control gene amplification product, wherein the set of control primers amplifies an internal control gene segment that is not specific to adaptive immune cells; and

(c) comparing a first number of assay samples that detectably contain said multiplicity of amplified rearranged DNA molecules of (b)(1) with a second number of assay samples that detectably contain said internal control gene amplification product of (b)(2), and therefrom quantifying the relative representation of adaptive immune cells in said test biological sample.

36. The method of claim 35, wherein each amplified rearranged DNA molecule is less than 600 nucleotides in length.

37. The method of claim 35, wherein each functional TCR or Ig V-encoding gene segment comprises a V gene recombination signal sequence (RSS) and each functional TCR or Ig J-encoding gene segment comprises a J gene RSS, and wherein each amplified rearranged DNA molecule comprises (i) at least 10, 20, 30 or 40 contiguous nucleotides of a sense strand of the TCR or Ig V-encoding gene segment, said at least 10, 20, 30 or 40 contiguous nucleotides being situated 5′

to the V gene RSS and (ii) at least 10, 20 or 30 contiguous nucleotides of a sense strand of the TCR or Ig J-encoding gene segment, said at least 10, 20 or 30 contiguous nucleotides being situated 3′

to the J gene RSS.

38. The method of claim 35, further comprising detecting a presence of at least ten adaptive immune cells per 10,000 cells in the mixture of cells.

39. The method of claim 35, wherein the adaptive immune cells are T cells.

40. The method of claim 35, wherein the adaptive immune cells are B cells.

41. The method of claim 35, wherein the biological sample is fresh tissue, frozen tissue, or fixed tissue.

42. The method of claim 35, wherein the rearranged TCR or Ig CDR3-encoding regions are selected from rearranged TCRα

CDR3-encoding regions, TCRβ

CDR3-encoding regions, TCRγ

CDR3-encoding regions, TCRδ

CDR3-encoding regions, IgH CDR3-encoding regions, Igκ

CDR3-encoding regions, and Igλ

CDR3-encoding regions.

43. The method of claim 35, wherein the sample comprises human cells, mouse cells, or rat cells.

44. The method of claim 35, wherein either or both of the first and second numbers of assay samples are determined by detecting fluorescence of a non-specific DNA-intercalating dye in the assay samples.

45. The method of claim 35, wherein the first number of assay samples is determined by detecting fluorescence of a labeled probe or of multiple labeled probes that specifically hybridize to the multiplicity of amplified rearranged DNA molecules, and the second number of assay samples is determined by detecting fluorescence of a labeled probe that specifically hybridizes to the internal control gene amplification products.

46. The method of claim 45, wherein the labeled probe that specifically hybridizes to the multiplicity of amplified rearranged DNA molecules comprises a sequence selected from SEQ ID NOS:

66 and 709-839, or one or more of the multiple labeled probes that specifically hybridize to the multiplicity of amplified rearranged DNA molecules comprise one or more sequence selected from SEQ ID NOS;

66 and 709-839.

47. The method of claim 35, wherein the sample comprises somatic tissue.

48. A method for assessing an effect of a therapeutic treatment on relative representation of adaptive immune cells in at least one tissue of a subject, the tissue comprising adaptive immune cells and cells that are not adaptive immune cells, the method comprising:

(I) obtaining one or a plurality of samples from a first tissue of the subject at one or a plurality of time points prior to administering the therapeutic treatment;

(II) obtaining one or a plurality of samples from a second tissue of the subject at one or a plurality of time points after administering the therapeutic treatment;

(III) for each of said samples from (I) and (II);

(a) distributing template DNA extracted from the sample to form a set of assay samples,

(b) amplifying said template DNA in the set of assay samples in a multiplex digital polymerase chain reaction (dPCR) that comprises;

(1) (i) a plurality of V-segment oligonucleotide primers comprising sequences selected from the group consisting of SEQ ID NOs;

1-52, 66-68, 221-238, 255-260, 262-267, 269, 272, 283, 286, 291, 292, 294-297, 301-326, 330, 338, 382, 405, 447-484, 644-695, 709-839, and 843-879 that are each independently capable of specifically hybridizing to at least one polynucleotide encoding a T cell receptor (TCR) V-region polypeptide or an immunoglobulin (Ig) V-region polypeptide, and

(ii) a plurality of J-segment oligonucleotide primers comprising sequences selected from the group consisting of SEQ ID NOs;

53-63, 65, 215-220, and 247 that are each independently capable of specifically hybridizing to at least one polynucleotide encoding a T cell receptor (TCR) J-region polypeptide or an immunoglobulin (Ig) J-region polypeptide,

wherein the V-segment and J-segment oligonucleotide primers are capable of amplifying in said multiplex dPCR at least 90% of all rearranged TCR or Ig CDR3-encoding regions in the sample to produce a multiplicity of amplified rearranged DNA molecules from the adaptive immune cells in the test sample; and

(2) a set of control primers capable of amplifying an internal control gene DNA segment present in every cell to produce internal control gene amplification products; and

(c) comparing a first number of assay samples that detectably contain said multiplicity of amplified rearranged DNA molecules of (b)(1) with a second number of assay samples that detectably contain said internal control gene amplification product of (b)(2), and therefrom quantifying the relative representation of adaptive immune cells in said sample; and

(IV) comparing the relative representation of adaptive immune cells in at least one sample obtained at a time point prior to administering the therapeutic treatment to the relative representation of adaptive immune cells in at least one sample obtained at a time point after administering the therapeutic treatment, and thereby assessing an effect of the therapeutic treatment on relative representation of adaptive immune cells in at least one tissue of a subject.

49. The method of claim 48, further comprising assessing a dose-related effect of the therapeutic treatment, wherein a plurality of samples are obtained from the second tissue of the subject at a plurality of time points after administering the therapeutic treatment, and wherein the therapeutic treatment is administered at a plurality of different dosages.

50. The method of claim 48, further comprising determining a prognosis for the subject receiving the therapeutic treatment based on a difference between the relative representation of adaptive immune cells in at least one sample obtained at a time point after administering the therapeutic treatment and the relative representation of adaptive immune cells in at least one sample obtained at a time point prior to administering the therapeutic treatment.

51. The method of claim 48, wherein:

(i) the subject has cancer and an increased relative representation of adaptive immune cells in at least one sample obtained at a time point after administering the therapeutic treatment compared to the relative representation of adaptive immune cells in at least one sample obtained at a time point prior to administering the therapeutic treatment, indicates a beneficial effect of the therapeutic treatment;

or

(ii) the subject has an autoimmune disease and a decreased relative representation of adaptive immune cells in at least one sample obtained at a time point after administering the therapeutic treatment compared to the relative representation of adaptive immune cells in at least one sample obtained at a time point prior to administering the therapeutic treatment, indicates a beneficial effect of the therapeutic treatment;

or

(iii) the subject has a transplanted organ and a decreased relative representation of adaptive immune cells in at least sample from the transplanted organ obtained at a time point after administering the therapeutic treatment compared to the relative representation of adaptive immune cells in at least one sample from the transplanted organ obtained at a time point prior to administering the therapeutic treatment, indicates a beneficial effect of the therapeutic treatment.